FDA Issues Guidance on Postapproval Pregnancy Safety Studies for Drugs

The FDA released final guidance recommending methodologies for studying drug and biologic safety during pregnancy in the postapproval setting. The guidance aims to improve collection of pregnancy safety data for marketed pharmaceutical products.